Wall Street analysts expect that Tilray Inc (NASDAQ:TLRY) will post earnings of ($0.14) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Tilray’s earnings, with estimates ranging from ($0.15) to ($0.13). The firm is expected to report its next quarterly earnings results after the market closes on Tuesday, November 13th.
According to Zacks, analysts expect that Tilray will report full-year earnings of ($0.48) per share for the current year, with EPS estimates ranging from ($0.53) to ($0.44). For the next financial year, analysts forecast that the firm will post earnings of ($0.18) per share, with EPS estimates ranging from ($0.29) to ($0.11). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Tilray.
Tilray (NASDAQ:TLRY) last posted its quarterly earnings data on Tuesday, August 28th. The company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.08). The business had revenue of $9.70 million during the quarter, compared to analyst estimates of $9.01 million. The business’s revenue was up 94.0% on a year-over-year basis.
Several research analysts have weighed in on TLRY shares. Benchmark started coverage on Tilray in a research report on Tuesday, October 16th. They issued a “buy” rating and a $200.00 price objective on the stock. Roth Capital started coverage on Tilray in a research report on Tuesday, August 14th. They issued a “buy” rating and a $35.00 price objective on the stock. Northland Securities cut Tilray from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 6th. Cowen started coverage on Tilray in a research report on Monday, August 13th. They issued an “outperform” rating and a $34.00 price objective on the stock. Finally, Zacks Investment Research lowered Tilray from a “hold” rating to a “sell” rating in a research note on Tuesday, October 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $135.67.
TLRY stock traded up $0.51 during midday trading on Friday, hitting $99.49. The company’s stock had a trading volume of 1,252,014 shares, compared to its average volume of 3,752,671. The company has a debt-to-equity ratio of 0.24, a current ratio of 0.62 and a quick ratio of 0.51. Tilray has a 1 year low of $20.10 and a 1 year high of $300.00.
Several institutional investors and hedge funds have recently modified their holdings of the business. Bank of Montreal Can bought a new stake in shares of Tilray in the third quarter valued at $2,467,000. Creative Planning bought a new stake in shares of Tilray in the third quarter valued at $1,329,000. Cambridge Investment Research Advisors Inc. bought a new stake in shares of Tilray in the third quarter valued at $1,123,000. Bouchey Financial Group Ltd bought a new stake in shares of Tilray in the third quarter valued at $316,000. Finally, Parker Investment Management LLC bought a new stake in shares of Tilray in the third quarter valued at $306,000. Hedge funds and other institutional investors own 0.02% of the company’s stock.
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Further Reading: How to Profit and Limit Losses With Stop Orders
Get a free copy of the Zacks research report on Tilray (TLRY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.